Navigation Links
Novel Test Identifies Leukemia Patients Likely to Respond to New Therapy

Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases// of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who’ll be most likely to benefit from it.

The research was led by Dr. Ari Melnick, assistant professor of developmental & molecular biology and medicine at Einstein, who also developed the new lymphoma therapy. The study appears in the February 20 issue of the Proceedings of the National Academy of Sciences.

Each year more than 60,000 Americans are diagnosed with B cell lymphomas—tumors of cells of the immune system that include Hodgkin’s and non-Hodgkin’s lymphomas. B cells are the immune-system cells that make antibodies. Genetic aberrations can cause B cells to multiply uncontrollably, causing B cell lymphomas.

Dr. Melnick’s study focused on a gene called BCL6. The protein it codes for is a transcriptional repressor, which means that it can shut off the functioning of genes in B cells and other cells of the immune system and prevent them from being expressed. The BCL6 protein is normally produced only during a specific stage of B cell development and is never made again. But deregulation of BCL6 can cause the protein to be produced when it shouldn’t be. The unwelcome presence of the BCL6 protein blocks the expression of important genes that normally protect cells from becoming cancerous. As a result, malignant B-cell lymphomas occur.

Mutations or chromosomal rearrangements that deregulate BCL6 are responsible for many cases of diffuse large B cell lymphoma—an aggressive cancer that accounts for up to 30 percent of newly diagnosed non-Hodgkin’s lymphoma cases. In a 2004 Nature Medicine article, Dr. Melnick and colleagues described a peptide, which they dubbed BPI, that showed promise in treating B-cell lymphomas by specifically blocking the cancer-causing effects of the BCL6 protein. But until now, there has been no way to distinguish between diffuse large B cell lymphomas that are caused by BCL6 deregulation and those cases in which BCL6 is expressed but doesn’t actually drive the cancer.

Dr. Melnick reasoned that those diffuse large B cell lymphomas that are caused by BCL6 deregulation should have a characteristic 'signature' in which the genes targeted by the BCL6 protein are either expressed (turned on) or not expressed. The researchers used state-of-the-art genomics technology to analyze a panel of diffuse large B cell lymphoma cell lines. They found a set of 485 BCL6-controlled genes and confirmed that all lymphomas with the BCL6 signature are killed by BPI while lymphomas without the signature are resistant to the therapy.

'Suitable lymphoma patients—those whose tumor cells exhibit this BCL6 signature --will now have access to a potent and specific therapy that is unlikely to cause the side effects associated with chemotherapy drugs,' says Dr. Melnick. 'At the same time, lymphoma patients who don’t fit this genetic profile will be spared a drug treatment that would be ineffective for them.'

Source-Bio-Bio Technolgy
SRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of ... Dental Day to individuals in need. The event is scheduled to take place on ... Day is to provide dental care to community members in need. Each patient will ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Health and wellness ... relevant to individuals in the event they are experiencing an illness. Migraines are a ... Americans that are afflicted with migraines would not wish the pain on their worst ...
(Date:2/5/2016)... ... 2016 , ... –This week, Atascadero water heater company First Call Plumbing ... To view the report, click here or see below. , There ... pros and cons, the type chosen is almost entirely up to personal preference. However, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016  Syneron Medical Ltd. (NASDAQ: ... announced today that William Griffing , Chief ... scheduled to participate in the Leerink Partners 5 ... 11, 2016 in New York City ... to meet with the Mr. Griffing and will ...
(Date:2/5/2016)... 5, 2016  As people age, it is natural ... recommended screenings and tests that are linked with certain ... for the majority of aging individuals, hearing health is ... the 37.5 million American adults who report some trouble ... make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology: